We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nevro (NVRO) Down 3.6% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
A month has gone by since the last earnings report for Nevro (NVRO - Free Report) . Shares have lost about 3.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Nevro due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Nevro Q1 Loss Wider Than Expected, Revenues Down Y/Y
Nevro reported first-quarter 2019 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of 66 cents. The company incurred a loss per share of 59 cents in the year-ago quarter.
The company posted revenues of $82.1 million, missing the Zacks Consensus Estimate by 6.1%. Revenues dropped 6.3% year over year.
Quarter Highlights
In the quarter under review, international revenues were $16.3 million, down 4% year over year but up 4% at constant currency (cc).
U.S. revenues for the quarter totaled $65.8 million, reflecting a 7% year-over-year drop. The decrease was due to the company’s decision to diminish the impact of high-volume product orders in the quarter.
Margins
Gross profit totaled $53.2 million, down 14.2% year over year. Gross margin was 64.8%, down 590 basis points.
Operating expenses rose 22.6% year over year to $95.5 million. Research and development expenses totaled $14.1 million, up 27.5% year over year. Sales, general and administrative expenses were up 22.1% year over year to $81.3 million.
Guidance
Nevro expects second-quarter 2019 worldwide revenue in the $87-$89 million range.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted -56.64% due to these changes.
VGM Scores
Currently, Nevro has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Nevro has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Nevro (NVRO) Down 3.6% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Nevro (NVRO - Free Report) . Shares have lost about 3.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Nevro due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Nevro Q1 Loss Wider Than Expected, Revenues Down Y/Y
Nevro reported first-quarter 2019 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of 66 cents. The company incurred a loss per share of 59 cents in the year-ago quarter.
The company posted revenues of $82.1 million, missing the Zacks Consensus Estimate by 6.1%. Revenues dropped 6.3% year over year.
Quarter Highlights
In the quarter under review, international revenues were $16.3 million, down 4% year over year but up 4% at constant currency (cc).
U.S. revenues for the quarter totaled $65.8 million, reflecting a 7% year-over-year drop. The decrease was due to the company’s decision to diminish the impact of high-volume product orders in the quarter.
Margins
Gross profit totaled $53.2 million, down 14.2% year over year. Gross margin was 64.8%, down 590 basis points.
Operating expenses rose 22.6% year over year to $95.5 million. Research and development expenses totaled $14.1 million, up 27.5% year over year.
Sales, general and administrative expenses were up 22.1% year over year to $81.3 million.
Guidance
Nevro expects second-quarter 2019 worldwide revenue in the $87-$89 million range.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted -56.64% due to these changes.
VGM Scores
Currently, Nevro has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Nevro has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.